Is MediciNova, Inc. (NASDAQ:MNOV) a buy in 2026?
Hold. MediciNova, Inc. is a wait-and-watch at today's price, not a fresh buy.
Twenty-year clinical option factory trading below cash utility, but the ALS readout is the whole ballgame and biology has burned believers before.
Where MNOV is headed
MediciNova has spent two decades doing the same thing: licensing molecules that big pharma abandoned, then pushing them through Phase 2 trials in indications where the FDA has shown willingness to bless small datasets. Ibudilast (MN-166) is the entire franchise. It's an oral PDE inhibitor originally approved in Japan for asthma in the 1980s, now being tested in progressive MS, ALS, glioblastoma, and substance use disorder. The company runs lean, burns roughly $6M a year, carries no debt, and sits on enough cash to keep the lights on into 2028 without a raise. That's the setup: a $71M market cap sitting on a portfolio of Phase 2 clinical readouts where any single positive result could triple the equity.
Read the full Compass Direction on MNOV
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $1.53).
See the full MNOV analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is MediciNova, Inc. (NASDAQ:MNOV) a buy in 2026?
Hold. MediciNova, Inc. is a wait-and-watch at today's price, not a fresh buy. Twenty-year clinical option factory trading below cash utility, but the ALS readout is the whole ballgame and biology has burned believers before.
What is MNOV's Compass Score?
MediciNova, Inc. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for MNOV?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the MNOV page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.